Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infectious diseases. Co. is conducting a Phase three clinical program focused on the infectious disease Clostridioides difficile Infection, or CDI. Co. is also developing new mechanism, precision antibiotics using its proprietary Discuva Platform. Co.'s primary CDI product candidate is ridinilazole, an orally administered small molecule antibiotic. Ridinilazole is designed to selectively target Clostridioides difficile bacteria while preserving the microbiome and thereby reduce CDI recurrence rates. The SMMT stock yearly return is shown above.
The yearly return on the SMMT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SMMT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|